Harbor Advisors LLC maintained its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, Holdings Channel reports. The firm owned 7,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Harbor Advisors LLC’s holdings in Gilead Sciences were worth $475,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Hendley & Co. Inc. increased its position in shares of Gilead Sciences by 7.9% in the fourth quarter. Hendley & Co. Inc. now owns 26,916 shares of the biopharmaceutical company’s stock valued at $1,927,000 after buying an additional 1,961 shares during the last quarter. RMB Capital Management LLC increased its position in shares of Gilead Sciences by 571.8% in the fourth quarter. RMB Capital Management LLC now owns 18,695 shares of the biopharmaceutical company’s stock valued at $1,339,000 after buying an additional 15,912 shares during the last quarter. Pekin Singer Strauss Asset Management IL increased its position in shares of Gilead Sciences by 36.5% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 15,796 shares of the biopharmaceutical company’s stock valued at $1,131,000 after buying an additional 4,227 shares during the last quarter. Dodge & Cox acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $233,000. Finally, Israel Discount Bank of New York GFN acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $534,000. 74.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.41% during trading on Friday, reaching $72.40. 7,029,745 shares of the company were exchanged. The stock’s 50-day moving average is $72.36 and its 200-day moving average is $68.77. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10. The firm has a market cap of $94.55 billion, a price-to-earnings ratio of 7.86 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the firm posted $3.08 earnings per share. The business’s revenue was down 8.2% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.87%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

TRADEMARK VIOLATION NOTICE: “Harbor Advisors LLC Holds Stake in Gilead Sciences, Inc. (GILD)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/harbor-advisors-llc-holds-stake-in-gilead-sciences-inc-gild.html.

Several research analysts recently weighed in on GILD shares. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC restated a “hold” rating and issued a $83.00 price objective on shares of Gilead Sciences in a research report on Thursday, July 27th. BMO Capital Markets restated an “outperform” rating and issued a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG restated a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, Cowen and Company restated an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research report on Thursday, July 27th. Twelve investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $80.31.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at $10,174,112. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 206,666 shares of company stock valued at $15,223,184. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.